- Home
- GNFT vs CHRS Comparison
GNFT vs CHRS Comparison
Compare GNFT & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNFT
- CHRS
- Stock Information
- Founded
- GNFT 1999
- CHRS 2010
- Country
- GNFT France
- CHRS United States
- Employees
- GNFT N/A
- CHRS N/A
- Industry
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GNFT Health Care
- CHRS Health Care
- Exchange
- GNFT Nasdaq
- CHRS Nasdaq
- Market Cap
- GNFT 186.3M
- CHRS 84.2M
- IPO Year
- GNFT 2019
- CHRS 2014
- Fundamental
- Price
- GNFT $3.75
- CHRS $0.90
- Analyst Decision
- GNFT Strong Buy
- CHRS Buy
- Analyst Count
- GNFT 1
- CHRS 3
- Target Price
- GNFT $13.00
- CHRS $4.68
- AVG Volume (30 Days)
- GNFT 3.8K
- CHRS 1.2M
- Earning Date
- GNFT 04-24-2025
- CHRS 08-07-2025
- Dividend Yield
- GNFT N/A
- CHRS N/A
- EPS Growth
- GNFT N/A
- CHRS N/A
- EPS
- GNFT 0.03
- CHRS N/A
- Revenue
- GNFT $73,187,701.00
- CHRS $272,251,000.00
- Revenue This Year
- GNFT $15.98
- CHRS N/A
- Revenue Next Year
- GNFT N/A
- CHRS $106.56
- P/E Ratio
- GNFT $120.71
- CHRS N/A
- Revenue Growth
- GNFT 105.01
- CHRS 19.87
- 52 Week Low
- GNFT $2.55
- CHRS $0.66
- 52 Week High
- GNFT $6.42
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- GNFT 44.52
- CHRS 59.04
- Support Level
- GNFT $3.44
- CHRS $0.73
- Resistance Level
- GNFT $3.81
- CHRS $0.82
- Average True Range (ATR)
- GNFT 0.17
- CHRS 0.04
- MACD
- GNFT -0.00
- CHRS 0.02
- Stochastic Oscillator
- GNFT 56.65
- CHRS 88.02
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.